Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Precision oncology testing	$ 156,229	$ 113,393
Development services and other	12,262	15,321
Total revenue	168,491	128,714
Costs and operating expenses:
Cost of precision oncology testing	59,306	45,106
Cost of development services and other	5,990	7,967
Research and development expense	83,802	93,128
Sales and marketing expense	80,425	76,123
General and administrative expense	38,651	40,445
Total costs and operating expenses	268,174	262,769
Loss from operations	(99,683)	(134,055)
Interest income	14,868	3,060
Interest expense	(645)	(644)
Other income (expense), net	(29,120)	(1,654)
Loss before provision for income taxes	(114,580)	(133,293)
Provision for income taxes	405	240
Net loss	$ (114,985)	$ (133,533)
Net loss per share, basic (in usd per share)	$ (0.94)	$ (1.30)
Net loss per share, diluted (in usd per share)	$ (0.94)	$ (1.30)
Weighted-average shares used in computing net loss per share, basic (in shares)	121,712	102,663
Weighted-average shares used in computing net loss per share, diluted (in shares)	121,712	102,663